# Protai Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protai-bio

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.protai.bio
- Total disclosed funding: $20M
- Latest round: Seed (Mar 15, 2023)
- Investors on record: 3

## About

Based in Tel Aviv, Israel, and founded in 2021, Protai Bio Ltd operates as an artificial intelligence (AI)-powered drug discovery company. Eran Seger (CEO) and Kirill Prevzner (CTO) are the co-founders of the company. In January 2022, Protai Bio raised USD 8 million in seed funding, co-led by new investors Grove Ventures and Pitango Venture Capital.

The company provides an end-to-end AI-based platform that thoroughly maps the course of the disease at the protein level, boosting the capacity to observe cellular function and, as a result, the discovery of new medications.

Protai Bio plans to use the seed funding received in January 2022 to further develop the company's platform, accelerate its discovery programs, and enhance its partnerships with pharmaceutical companies.

## Funding rounds

- Seed, Mar 15, 2023, $12M — Pitango, Maj Invest, Grove
- Seed, Jan 5, 2022, $8M — Pitango, Grove

## Investors

- Pitango (https://capitalatlas.ai/funds/pitango) — Seed
- Grove (https://capitalatlas.ai/funds/grove) — Seed
- Maj Invest (https://capitalatlas.ai/funds/maj-invest) — Seed